Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *


Products » Items » NovoSeven RT 250KIU


To avoid
As a precautionary measure

Contraindicated
NovoSeven RT 250KIU :
Type Medicine Authorised
Originator Biotech (NovoSeven RT 250KIU)
Agent Mersaco
Distributor Mersaco
Laboratory Novo Nordisk
Responsible Party Novo Nordisk AS
Origin Denmark
Manufacturer Novo Nordisk AS
Origin Denmark
ATC B02BD08

Your comment will appear shortly after approval


Different Units By MoH Code

Revision Date : 11/01/2013

NovoSeven RT 250KIU  MoH 5541 :
Form Powder and solvent for solution for injection
Packaging Pre-filled Syringes + Vials (Type I glass)
Package Size 1+1
Strength 5mg (250KIU)
Public Price 5033515 L.L.
Stratum E2
NSSF
Quarantine
Reg. Number 218017/09
Submission date 01/01/2009
Registration Year 2009





Price Comparison

Country: Italy
Package Size: 1+1x5.2ml
Public Price: 5395.61 EUR ( 99,171,581.58 LBP )
Pack size unit used: 1
Cost/Unit: 5395,61 EUR ( 99,160,369.75 LBP )
Exfactory Price: 3269.25 EUR
Pricing Date: 17/12/2019
Type: Medicine Authorised

Country: Qatar
Package Size: 1 powder vial + 1 Solvent pre-filled syringe + vial adapter
Public Price: 19816 QAR ( 82,247,496.96 LBP )
Pack size unit used: 1
Cost/Unit: 19816 QAR ( 82,247,496.96 LBP )
Pharmacy Price: 16277.33865628 QAR ( 67560070.73321 LBP )
Pricing Date: 28/01/2021
Type: Medicine Authorised

Country: Oman
Package Size: 1+1
Public Price: 2086.42 OMR ( 81,997,349.21 LBP )
Pack size unit used: 1
Cost/Unit: 2086,42 OMR ( 81,980,843.00 LBP )
Pricing Date: 19/02/2021
Type: Medicine Authorised

Country: Kuweit
Package Size: 1+1
Public Price: 1596.98 KWD ( 79,162,426.36 LBP )
Pack size unit used: 1
Cost/Unit: 1596,98 KWD ( 79,113,847.68 LBP )
Pharmacy Price: 1349.17 KWD ( 66878464.8336 LBP )
Pricing Date: 07/02/2021
Type: Medicine Authorised

Country: Abu Dhabi
Package Size: 1+1
Public Price: 18517 AED ( 76,122,646.32 LBP )
Pack size unit used: 1
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Pharmacy Price: 15773.8 AED ( 64845460.848 LBP )
Pricing Date: 27/01/2021
Type: Medicine Authorised

Country: UAE
Package Size: 1 Vial (Powder) + 1 Solvent Vial (2.1ml)
Public Price: 18517 AED ( 76,122,646.32 LBP )
Pack size unit used: 1
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Pharmacy Price: 15773.78 AED ( 64845378.6288 LBP )
Pricing Date: 21/08/2019
Type: Medicine Authorised

Country: Switzerland
Package Size: 1+1
Public Price: 4370.8 CHF ( 74,566,940.70 LBP )
Pack size unit used: 1
Cost/Unit: 4370,8 CHF ( 74,553,292.50 LBP )
Exfactory Price: 4224.2 CHF
Pricing Date: 04/04/2021
Type: Medicine Authorised

Country: Finland
Package Size: 1+1
Public Price: 3888.15 EUR ( 71,464,391.41 LBP )
Pack size unit used: 1
Cost/Unit: 3888,15 EUR ( 71,461,634.40 LBP )
Reference: Kela
Pricing Date: 22/04/2021
Type: Medicine Authorised

Country: Bahrain
Package Size: 1+1
Public Price: 1761.26 BHD ( 70,663,107.37 LBP )
Pack size unit used: 1
Cost/Unit: 1761,26 BHD ( 70,652,675.97 LBP )
Reference: nhra
Pricing Date: 09/02/2021
Type: Medicine Authorised

Country: Denmark
Package Size: 1+1
Public Price: 26563.3 DKK ( 65,371,484.40 LBP )
Pack size unit used: 1
Cost/Unit: 26563,3 DKK ( 65,370,746.11 LBP )
Pharmacy Price: 19744.6 DKK ( 48590868.262 LBP )
Reference: Danish Medicine Agency
Pricing Date: 19/05/2021
Type: Medicine Authorised

Country: Iceland
Package Size: 1+1
Public Price: 532896 ISK ( 59,076,850.56 LBP )
Pack size unit used: 1
Cost/Unit: 532896 ISK ( 59,076,850.56 LBP )
Pharmacy Price: 423362 ISK ( 46933911.32 LBP )
Reference: Icelandic Medicines Agency
Pricing Date: 01/04/2020
Type: Medicine Authorised

Country: Czech Republic
Package Size: 1+1x5.2ml
Public Price: 85264.46 CZK ( 58,897,278.39 LBP )
Pack size unit used: 1
Cost/Unit: 85264,46 CZK ( 58,896,960.64 LBP )
Reference: SUKL
Pricing Date: 28/02/2020
Type: Medicine Authorised

Country: Spain
Package Size: 1 vial + 1xdisolvente
Public Price: 3062.98 EUR ( 56,297,725.55 LBP )
Pack size unit used: 1
Cost/Unit: 3062,98 EUR ( 56,279,713.10 LBP )
Reference: Agencia Española de Medicamentos y Productos Sanitarios
Pricing Date: 06/05/2021
Type: Medicine Non Marketed

Country: France
Package Size: 1+1
Public Price: 3040 EUR ( 55,875,352.00 LBP )
Pack size unit used: 1
Cost/Unit: 3040 EUR ( 55,875,352.00 LBP )
Reference: ansm
Pricing Date: 15/05/2021
Type: Medicine Authorised

Country: KSA
Package Size: 3mg
Public Price: 13202.15 SAR ( 53,209,681.32 LBP )
Pack size unit used: 1
Cost/Unit: 13202,15 SAR ( 53,209,076.76 LBP )
Reference: sfda
Pricing Date: 16/01/2021
Type: Medicine Authorised

Country: UK
Package Size: 1+1
Public Price: 2626 GBP ( 52,915,922.02 LBP )
Pack size unit used: 1
Cost/Unit: 2626 GBP ( 52,915,922.02 LBP )
Reference: DMD
Pricing Date: 08/03/2021
Type: Medicine Authorised

Country: Norway
Package Size: 1
Public Price: 30097 NOK ( 52,075,936.19 LBP )
Pack size unit used: 1
Cost/Unit: 30097 NOK ( 52,075,936.19 LBP )
Pharmacy Price: 23577.07 NOK ( 40794696.9089 LBP )
Reference: Norwegian Medicine Agency
Pricing Date: 01/04/2020
Type: Medicine Authorised

Country: Sweden
Package Size: 1+1
Public Price: 28482.76 SEK ( 51,272,101.10 LBP )
Pack size unit used: 1
Cost/Unit: 28482,76 SEK ( 51,270,733.02 LBP )
Pharmacy Price: 27878.93 SEK ( 50185140.6823 LBP )
Pricing Date: 23/04/2020
Type: Medicine Authorised

Country: Belgium
Package Size: 1+1x5.2ml
Public Price: 2662 EUR ( 48,927,693.10 LBP )
Pack size unit used: 1
Cost/Unit: 2662 EUR ( 48,927,693.10 LBP )
Medica Comments: Withdrawn on november 2018
Reference: cbip
Pricing Date: 02/12/2020
Type: Medicine Authorised

Country: Turkey
Package Size: 1
Public Price: 12895.82 TRY ( 24,768,872.52 LBP )
Pack size unit used: 1
Cost/Unit: 12895,82 TRY ( 24,767,297.55 LBP )
Pricing Date: 28/10/2020
Type: Medicine Authorised

Country: Lebanon
Form: Powder and solvent for solution for injection
Package Size: 1+1
Public Price: 5033515 LBP ( 5,033,515.00 LBP )
Pack size unit used: 1
Cost/Unit: 5033515 LBP ( 5,033,515.00 LBP )
Pricing Date: 10/01/2024

Country: The Netherlands
Package Size: 1
Reference: Zorginstituut Nederland
Pricing Date: 15/06/2019
Type: Medicine Non Marketed

Country: Greece
Package Size: 1+1
Reference: National Organization for Medicines
Pricing Date: 25/03/2019
Type: Medicine Non Marketed

Country: New Zealand
Package Size: 1 inj
Exfactory Price: 5891.5 NZD
Reference: New Zealand Pharmaceutical Management Agency
Pricing Date: 01/04/2020
Type: Medicine Authorised

Country: Portugal
Package Size: 1+1
Reference: Autoridade Nacional do Medicamento e Produtos de Saúde
Pricing Date: 22/04/2019

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries


Note

Acquired haemophilia :
Cost/Unit: 5395,61 EUR ( 99,160,369.75 LBP )
Cost/Day: 10791,22 EUR ( 198,339,119.55 LBP )
Cost/Month: 10791,22 EUR ( 198,339,119.55 LBP )
Congenital FVII deficiency :
Cost/Unit: 5395,61 EUR ( 99,160,369.75 LBP )
Cost/Day: 10791,22 EUR ( 198,339,119.55 LBP )
Cost/Month: 10791,22 EUR ( 198,339,119.55 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 5395,61 EUR ( 99,160,369.75 LBP )
Cost/Day: 10791,22 EUR ( 198,339,119.55 LBP )
Cost/Month: 10791,22 EUR ( 198,339,119.55 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 5395,61 EUR ( 99,160,369.75 LBP )
Cost/Day: 10791,22 EUR ( 198,339,119.55 LBP )
Cost/Month: 10791,22 EUR ( 198,339,119.55 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 5395,61 EUR ( 99,160,369.75 LBP )
Cost/Day: 10791,22 EUR ( 198,339,119.55 LBP )
Cost/Month: 10791,22 EUR ( 198,339,119.55 LBP )
Acquired haemophilia :
Cost/Unit: 19816 QAR ( 82,247,496.96 LBP )
Cost/Day: 39632 QAR ( 164,494,993.92 LBP )
Cost/Month: 39632 QAR ( 164,494,993.92 LBP )
Congenital FVII deficiency :
Cost/Unit: 19816 QAR ( 82,247,496.96 LBP )
Cost/Day: 39632 QAR ( 164,494,993.92 LBP )
Cost/Month: 39632 QAR ( 164,494,993.92 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 19816 QAR ( 82,247,496.96 LBP )
Cost/Day: 39632 QAR ( 164,494,993.92 LBP )
Cost/Month: 39632 QAR ( 164,494,993.92 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 19816 QAR ( 82,247,496.96 LBP )
Cost/Day: 39632 QAR ( 164,494,993.92 LBP )
Cost/Month: 39632 QAR ( 164,494,993.92 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 19816 QAR ( 82,247,496.96 LBP )
Cost/Day: 39632 QAR ( 164,494,993.92 LBP )
Cost/Month: 39632 QAR ( 164,494,993.92 LBP )
Acquired haemophilia :
Cost/Unit: 2086,42 OMR ( 81,980,843.00 LBP )
Cost/Day: 4172,84 OMR ( 163,961,686.00 LBP )
Cost/Month: 4172,84 OMR ( 163,961,686.00 LBP )
Congenital FVII deficiency :
Cost/Unit: 2086,42 OMR ( 81,980,843.00 LBP )
Cost/Day: 4172,84 OMR ( 163,961,686.00 LBP )
Cost/Month: 4172,84 OMR ( 163,961,686.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 2086,42 OMR ( 81,980,843.00 LBP )
Cost/Day: 4172,84 OMR ( 163,961,686.00 LBP )
Cost/Month: 4172,84 OMR ( 163,961,686.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 2086,42 OMR ( 81,980,843.00 LBP )
Cost/Day: 4172,84 OMR ( 163,961,686.00 LBP )
Cost/Month: 4172,84 OMR ( 163,961,686.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 2086,42 OMR ( 81,980,843.00 LBP )
Cost/Day: 4172,84 OMR ( 163,961,686.00 LBP )
Cost/Month: 4172,84 OMR ( 163,961,686.00 LBP )
Acquired haemophilia :
Cost/Unit: 1596,98 KWD ( 79,113,847.68 LBP )
Cost/Day: 3193,96 KWD ( 158,277,265.44 LBP )
Cost/Month: 3193,96 KWD ( 158,277,265.44 LBP )
Congenital FVII deficiency :
Cost/Unit: 1596,98 KWD ( 79,113,847.68 LBP )
Cost/Day: 3193,96 KWD ( 158,277,265.44 LBP )
Cost/Month: 3193,96 KWD ( 158,277,265.44 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 1596,98 KWD ( 79,113,847.68 LBP )
Cost/Day: 3193,96 KWD ( 158,277,265.44 LBP )
Cost/Month: 3193,96 KWD ( 158,277,265.44 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 1596,98 KWD ( 79,113,847.68 LBP )
Cost/Day: 3193,96 KWD ( 158,277,265.44 LBP )
Cost/Month: 3193,96 KWD ( 158,277,265.44 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 1596,98 KWD ( 79,113,847.68 LBP )
Cost/Day: 3193,96 KWD ( 158,277,265.44 LBP )
Cost/Month: 3193,96 KWD ( 158,277,265.44 LBP )
Acquired haemophilia :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Congenital FVII deficiency :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Acquired haemophilia :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Congenital FVII deficiency :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 18517 AED ( 76,122,646.32 LBP )
Cost/Day: 37034 AED ( 152,245,292.64 LBP )
Cost/Month: 37034 AED ( 152,245,292.64 LBP )
Acquired haemophilia :
Cost/Unit: 4370,8 CHF ( 74,553,292.50 LBP )
Cost/Day: 8741,6 CHF ( 149,123,645.25 LBP )
Cost/Month: 8741,6 CHF ( 149,123,645.25 LBP )
Congenital FVII deficiency :
Cost/Unit: 4370,8 CHF ( 74,553,292.50 LBP )
Cost/Day: 8741,6 CHF ( 149,123,645.25 LBP )
Cost/Month: 8741,6 CHF ( 149,123,645.25 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 4370,8 CHF ( 74,553,292.50 LBP )
Cost/Day: 8741,6 CHF ( 149,123,645.25 LBP )
Cost/Month: 8741,6 CHF ( 149,123,645.25 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 4370,8 CHF ( 74,553,292.50 LBP )
Cost/Day: 8741,6 CHF ( 149,123,645.25 LBP )
Cost/Month: 8741,6 CHF ( 149,123,645.25 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 4370,8 CHF ( 74,553,292.50 LBP )
Cost/Day: 8741,6 CHF ( 149,123,645.25 LBP )
Cost/Month: 8741,6 CHF ( 149,123,645.25 LBP )
Acquired haemophilia :
Cost/Unit: 3888,15 EUR ( 71,461,634.40 LBP )
Cost/Day: 7776,3 EUR ( 142,923,268.80 LBP )
Cost/Month: 7776,3 EUR ( 142,923,268.80 LBP )
Congenital FVII deficiency :
Cost/Unit: 3888,15 EUR ( 71,461,634.40 LBP )
Cost/Day: 7776,3 EUR ( 142,923,268.80 LBP )
Cost/Month: 7776,3 EUR ( 142,923,268.80 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 3888,15 EUR ( 71,461,634.40 LBP )
Cost/Day: 7776,3 EUR ( 142,923,268.80 LBP )
Cost/Month: 7776,3 EUR ( 142,923,268.80 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 3888,15 EUR ( 71,461,634.40 LBP )
Cost/Day: 7776,3 EUR ( 142,923,268.80 LBP )
Cost/Month: 7776,3 EUR ( 142,923,268.80 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 3888,15 EUR ( 71,461,634.40 LBP )
Cost/Day: 7776,3 EUR ( 142,923,268.80 LBP )
Cost/Month: 7776,3 EUR ( 142,923,268.80 LBP )
Acquired haemophilia :
Cost/Unit: 1761,26 BHD ( 70,652,675.97 LBP )
Cost/Day: 3522,52 BHD ( 141,305,351.94 LBP )
Cost/Month: 3522,52 BHD ( 141,305,351.94 LBP )
Congenital FVII deficiency :
Cost/Unit: 1761,26 BHD ( 70,652,675.97 LBP )
Cost/Day: 3522,52 BHD ( 141,305,351.94 LBP )
Cost/Month: 3522,52 BHD ( 141,305,351.94 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 1761,26 BHD ( 70,652,675.97 LBP )
Cost/Day: 3522,52 BHD ( 141,305,351.94 LBP )
Cost/Month: 3522,52 BHD ( 141,305,351.94 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 1761,26 BHD ( 70,652,675.97 LBP )
Cost/Day: 3522,52 BHD ( 141,305,351.94 LBP )
Cost/Month: 3522,52 BHD ( 141,305,351.94 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 1761,26 BHD ( 70,652,675.97 LBP )
Cost/Day: 3522,52 BHD ( 141,305,351.94 LBP )
Cost/Month: 3522,52 BHD ( 141,305,351.94 LBP )
Acquired haemophilia :
Cost/Unit: 26563,3 DKK ( 65,370,746.11 LBP )
Cost/Day: 53126,6 DKK ( 130,741,492.22 LBP )
Cost/Month: 53126,6 DKK ( 130,741,492.22 LBP )
Congenital FVII deficiency :
Cost/Unit: 26563,3 DKK ( 65,370,746.11 LBP )
Cost/Day: 53126,6 DKK ( 130,741,492.22 LBP )
Cost/Month: 53126,6 DKK ( 130,741,492.22 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 26563,3 DKK ( 65,370,746.11 LBP )
Cost/Day: 53126,6 DKK ( 130,741,492.22 LBP )
Cost/Month: 53126,6 DKK ( 130,741,492.22 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 26563,3 DKK ( 65,370,746.11 LBP )
Cost/Day: 53126,6 DKK ( 130,741,492.22 LBP )
Cost/Month: 53126,6 DKK ( 130,741,492.22 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 26563,3 DKK ( 65,370,746.11 LBP )
Cost/Day: 53126,6 DKK ( 130,741,492.22 LBP )
Cost/Month: 53126,6 DKK ( 130,741,492.22 LBP )
Acquired haemophilia :
Cost/Unit: 532896 ISK ( 59,076,850.56 LBP )
Cost/Day: 1065792 ISK ( 118,153,701.12 LBP )
Cost/Month: 1065792 ISK ( 118,153,701.12 LBP )
Congenital FVII deficiency :
Cost/Unit: 532896 ISK ( 59,076,850.56 LBP )
Cost/Day: 1065792 ISK ( 118,153,701.12 LBP )
Cost/Month: 1065792 ISK ( 118,153,701.12 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 532896 ISK ( 59,076,850.56 LBP )
Cost/Day: 1065792 ISK ( 118,153,701.12 LBP )
Cost/Month: 1065792 ISK ( 118,153,701.12 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 532896 ISK ( 59,076,850.56 LBP )
Cost/Day: 1065792 ISK ( 118,153,701.12 LBP )
Cost/Month: 1065792 ISK ( 118,153,701.12 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 532896 ISK ( 59,076,850.56 LBP )
Cost/Day: 1065792 ISK ( 118,153,701.12 LBP )
Cost/Month: 1065792 ISK ( 118,153,701.12 LBP )
Acquired haemophilia :
Cost/Unit: 85264,46 CZK ( 58,896,960.64 LBP )
Cost/Day: 170528,92 CZK ( 117,793,921.28 LBP )
Cost/Month: 170528,92 CZK ( 117,793,921.28 LBP )
Congenital FVII deficiency :
Cost/Unit: 85264,46 CZK ( 58,896,960.64 LBP )
Cost/Day: 170528,92 CZK ( 117,793,921.28 LBP )
Cost/Month: 170528,92 CZK ( 117,793,921.28 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 85264,46 CZK ( 58,896,960.64 LBP )
Cost/Day: 170528,92 CZK ( 117,793,921.28 LBP )
Cost/Month: 170528,92 CZK ( 117,793,921.28 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 85264,46 CZK ( 58,896,960.64 LBP )
Cost/Day: 170528,92 CZK ( 117,793,921.28 LBP )
Cost/Month: 170528,92 CZK ( 117,793,921.28 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 85264,46 CZK ( 58,896,960.64 LBP )
Cost/Day: 170528,92 CZK ( 117,793,921.28 LBP )
Cost/Month: 170528,92 CZK ( 117,793,921.28 LBP )
Acquired haemophilia :
Cost/Unit: 3062,98 EUR ( 56,279,713.10 LBP )
Cost/Day: 6125,96 EUR ( 112,577,806.25 LBP )
Cost/Month: 6125,96 EUR ( 112,577,806.25 LBP )
Congenital FVII deficiency :
Cost/Unit: 3062,98 EUR ( 56,279,713.10 LBP )
Cost/Day: 6125,96 EUR ( 112,577,806.25 LBP )
Cost/Month: 6125,96 EUR ( 112,577,806.25 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 3062,98 EUR ( 56,279,713.10 LBP )
Cost/Day: 6125,96 EUR ( 112,577,806.25 LBP )
Cost/Month: 6125,96 EUR ( 112,577,806.25 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 3062,98 EUR ( 56,279,713.10 LBP )
Cost/Day: 6125,96 EUR ( 112,577,806.25 LBP )
Cost/Month: 6125,96 EUR ( 112,577,806.25 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 3062,98 EUR ( 56,279,713.10 LBP )
Cost/Day: 6125,96 EUR ( 112,577,806.25 LBP )
Cost/Month: 6125,96 EUR ( 112,577,806.25 LBP )
Acquired haemophilia :
Cost/Unit: 3040 EUR ( 55,875,352.00 LBP )
Cost/Day: 6080 EUR ( 111,750,704.00 LBP )
Cost/Month: 6080 EUR ( 111,750,704.00 LBP )
Congenital FVII deficiency :
Cost/Unit: 3040 EUR ( 55,875,352.00 LBP )
Cost/Day: 6080 EUR ( 111,750,704.00 LBP )
Cost/Month: 6080 EUR ( 111,750,704.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 3040 EUR ( 55,875,352.00 LBP )
Cost/Day: 6080 EUR ( 111,750,704.00 LBP )
Cost/Month: 6080 EUR ( 111,750,704.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 3040 EUR ( 55,875,352.00 LBP )
Cost/Day: 6080 EUR ( 111,750,704.00 LBP )
Cost/Month: 6080 EUR ( 111,750,704.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 3040 EUR ( 55,875,352.00 LBP )
Cost/Day: 6080 EUR ( 111,750,704.00 LBP )
Cost/Month: 6080 EUR ( 111,750,704.00 LBP )
Acquired haemophilia :
Cost/Unit: 13202,15 SAR ( 53,209,076.76 LBP )
Cost/Day: 26404,3 SAR ( 106,418,153.52 LBP )
Cost/Month: 26404,3 SAR ( 106,418,153.52 LBP )
Congenital FVII deficiency :
Cost/Unit: 13202,15 SAR ( 53,209,076.76 LBP )
Cost/Day: 26404,3 SAR ( 106,418,153.52 LBP )
Cost/Month: 26404,3 SAR ( 106,418,153.52 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 13202,15 SAR ( 53,209,076.76 LBP )
Cost/Day: 26404,3 SAR ( 106,418,153.52 LBP )
Cost/Month: 26404,3 SAR ( 106,418,153.52 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 13202,15 SAR ( 53,209,076.76 LBP )
Cost/Day: 26404,3 SAR ( 106,418,153.52 LBP )
Cost/Month: 26404,3 SAR ( 106,418,153.52 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 13202,15 SAR ( 53,209,076.76 LBP )
Cost/Day: 26404,3 SAR ( 106,418,153.52 LBP )
Cost/Month: 26404,3 SAR ( 106,418,153.52 LBP )
Acquired haemophilia :
Cost/Unit: 2626 GBP ( 52,915,922.02 LBP )
Cost/Day: 5252 GBP ( 105,831,844.04 LBP )
Cost/Month: 5252 GBP ( 105,831,844.04 LBP )
Congenital FVII deficiency :
Cost/Unit: 2626 GBP ( 52,915,922.02 LBP )
Cost/Day: 5252 GBP ( 105,831,844.04 LBP )
Cost/Month: 5252 GBP ( 105,831,844.04 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 2626 GBP ( 52,915,922.02 LBP )
Cost/Day: 5252 GBP ( 105,831,844.04 LBP )
Cost/Month: 5252 GBP ( 105,831,844.04 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 2626 GBP ( 52,915,922.02 LBP )
Cost/Day: 5252 GBP ( 105,831,844.04 LBP )
Cost/Month: 5252 GBP ( 105,831,844.04 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 2626 GBP ( 52,915,922.02 LBP )
Cost/Day: 5252 GBP ( 105,831,844.04 LBP )
Cost/Month: 5252 GBP ( 105,831,844.04 LBP )
Acquired haemophilia :
Cost/Unit: 30097 NOK ( 52,075,936.19 LBP )
Cost/Day: 60194 NOK ( 104,151,872.38 LBP )
Cost/Month: 60194 NOK ( 104,151,872.38 LBP )
Congenital FVII deficiency :
Cost/Unit: 30097 NOK ( 52,075,936.19 LBP )
Cost/Day: 60194 NOK ( 104,151,872.38 LBP )
Cost/Month: 60194 NOK ( 104,151,872.38 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 30097 NOK ( 52,075,936.19 LBP )
Cost/Day: 60194 NOK ( 104,151,872.38 LBP )
Cost/Month: 60194 NOK ( 104,151,872.38 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 30097 NOK ( 52,075,936.19 LBP )
Cost/Day: 60194 NOK ( 104,151,872.38 LBP )
Cost/Month: 60194 NOK ( 104,151,872.38 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 30097 NOK ( 52,075,936.19 LBP )
Cost/Day: 60194 NOK ( 104,151,872.38 LBP )
Cost/Month: 60194 NOK ( 104,151,872.38 LBP )
Acquired haemophilia :
Cost/Unit: 28482,76 SEK ( 51,270,733.02 LBP )
Cost/Day: 56965,52 SEK ( 102,543,266.15 LBP )
Cost/Month: 56965,52 SEK ( 102,543,266.15 LBP )
Congenital FVII deficiency :
Cost/Unit: 28482,76 SEK ( 51,270,733.02 LBP )
Cost/Day: 56965,52 SEK ( 102,543,266.15 LBP )
Cost/Month: 56965,52 SEK ( 102,543,266.15 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 28482,76 SEK ( 51,270,733.02 LBP )
Cost/Day: 56965,52 SEK ( 102,543,266.15 LBP )
Cost/Month: 56965,52 SEK ( 102,543,266.15 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 28482,76 SEK ( 51,270,733.02 LBP )
Cost/Day: 56965,52 SEK ( 102,543,266.15 LBP )
Cost/Month: 56965,52 SEK ( 102,543,266.15 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 28482,76 SEK ( 51,270,733.02 LBP )
Cost/Day: 56965,52 SEK ( 102,543,266.15 LBP )
Cost/Month: 56965,52 SEK ( 102,543,266.15 LBP )
Acquired haemophilia :
Cost/Unit: 2662 EUR ( 48,927,693.10 LBP )
Cost/Day: 5324 EUR ( 97,855,386.20 LBP )
Cost/Month: 5324 EUR ( 97,855,386.20 LBP )
Congenital FVII deficiency :
Cost/Unit: 2662 EUR ( 48,927,693.10 LBP )
Cost/Day: 5324 EUR ( 97,855,386.20 LBP )
Cost/Month: 5324 EUR ( 97,855,386.20 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 2662 EUR ( 48,927,693.10 LBP )
Cost/Day: 5324 EUR ( 97,855,386.20 LBP )
Cost/Month: 5324 EUR ( 97,855,386.20 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 2662 EUR ( 48,927,693.10 LBP )
Cost/Day: 5324 EUR ( 97,855,386.20 LBP )
Cost/Month: 5324 EUR ( 97,855,386.20 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 2662 EUR ( 48,927,693.10 LBP )
Cost/Day: 5324 EUR ( 97,855,386.20 LBP )
Cost/Month: 5324 EUR ( 97,855,386.20 LBP )
Acquired haemophilia :
Cost/Unit: 12895,82 TRY ( 24,767,297.55 LBP )
Cost/Day: 25791,64 TRY ( 49,536,515.79 LBP )
Cost/Month: 25791,64 TRY ( 49,536,515.79 LBP )
Congenital FVII deficiency :
Cost/Unit: 12895,82 TRY ( 24,767,297.55 LBP )
Cost/Day: 25791,64 TRY ( 49,536,515.79 LBP )
Cost/Month: 25791,64 TRY ( 49,536,515.79 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 12895,82 TRY ( 24,767,297.55 LBP )
Cost/Day: 25791,64 TRY ( 49,536,515.79 LBP )
Cost/Month: 25791,64 TRY ( 49,536,515.79 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 12895,82 TRY ( 24,767,297.55 LBP )
Cost/Day: 25791,64 TRY ( 49,536,515.79 LBP )
Cost/Month: 25791,64 TRY ( 49,536,515.79 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 12895,82 TRY ( 24,767,297.55 LBP )
Cost/Day: 25791,64 TRY ( 49,536,515.79 LBP )
Cost/Month: 25791,64 TRY ( 49,536,515.79 LBP )
Acquired haemophilia :
Cost/Unit: 5033515 LBP ( 5,033,515.00 LBP )
Cost/Day: 10067030 LBP ( 10,067,030.00 LBP )
Cost/Month: 10067030 LBP ( 10,067,030.00 LBP )
Congenital FVII deficiency :
Cost/Unit: 5033515 LBP ( 5,033,515.00 LBP )
Cost/Day: 10067030 LBP ( 10,067,030.00 LBP )
Cost/Month: 10067030 LBP ( 10,067,030.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
Cost/Unit: 5033515 LBP ( 5,033,515.00 LBP )
Cost/Day: 10067030 LBP ( 10,067,030.00 LBP )
Cost/Month: 10067030 LBP ( 10,067,030.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
Cost/Unit: 5033515 LBP ( 5,033,515.00 LBP )
Cost/Day: 10067030 LBP ( 10,067,030.00 LBP )
Cost/Month: 10067030 LBP ( 10,067,030.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
Cost/Unit: 5033515 LBP ( 5,033,515.00 LBP )
Cost/Day: 10067030 LBP ( 10,067,030.00 LBP )
Cost/Month: 10067030 LBP ( 10,067,030.00 LBP )

Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info